<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164122</url>
  </required_header>
  <id_info>
    <org_study_id>2016-34</org_study_id>
    <secondary_id>2016-002648-18</secondary_id>
    <nct_id>NCT03164122</nct_id>
  </id_info>
  <brief_title>EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA</brief_title>
  <acronym>AMIPREP</acronym>
  <official_title>EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, the emergence of biotherapies has allowed the use of intra-articular injections of&#xD;
      autologous plasma rich platelet (PRP). Their use is widespread since 2010 and is based on the&#xD;
      demonstration that platelets-enriched plasma, by virtue of its growth factors concentration,&#xD;
      stimulates in vitro and in vivo cartilage regeneration in preclinical models. Recent&#xD;
      literature highlights that these autologous products are very well tolerated by humans. PRP,&#xD;
      as an intra-articular injection therapy, seems to be an autologous biological medicine,&#xD;
      innovative for cartilage injury reparation and showing good primary results for this&#xD;
      indication.&#xD;
&#xD;
      Adipose tissue contains stromal-vascular fraction (SVF), in which are located a large&#xD;
      proportion of mesenchymal multipotent stem cells (Adipose-derived stem cells, ADSCs) able to&#xD;
      differentiate into several cellular lines in vitro and in vivo, including cartilage cells.&#xD;
&#xD;
      The association of microfat and PRP is interesting in order to potentiate trophic and&#xD;
      regenerative effects on damaged cartilage site. The combination of these two products,&#xD;
      respectively rich in autologous multipotent stem cells and growth factors, aims to create an&#xD;
      optimal environment for cartilage cells regeneration. Furthermore, microfat semi solid phase&#xD;
      is playing the role of a nutritive support matrix which contains and limits the diffusion and&#xD;
      resorption of PRP liquid while allowing progressive growth factors release on the injection&#xD;
      site.&#xD;
&#xD;
      The hypothesis of this project is that standardized injection of an innovative treatment&#xD;
      (microfat and autologous PRP) should allow delay the use of invasive surgical therapy in the&#xD;
      treatment of wrist osteoarthritis. This minimally invasive treatment could provide a curative&#xD;
      second line treatment in case of medical treatment failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Material and methods:&#xD;
&#xD;
      This research protocol aims to evaluate the safety of intra-articular injection of a mixture&#xD;
      of autologous microfat associated with autologous PRP for radiocarpal osteoarthritis&#xD;
      resistant to medical treatment.&#xD;
&#xD;
      This is a prospective, longitudinal, intrasubject, single-center clinical trial phase I-IIa&#xD;
      evaluating the safety and feasibility of this innovative treatment.&#xD;
&#xD;
      Twelve patients will receive an intra-articular injection of 4 ml of an homogeneous mixture&#xD;
      of autologous PRP (2ml) and microfat (2ml).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 22, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the safety</measure>
    <time_frame>1 MONTH</time_frame>
    <description>By the number of Adverse event related to the traitment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of pain</measure>
    <time_frame>3 ,6, 12 months</time_frame>
    <description>with the Visual Analogue Scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of wrist pain</measure>
    <time_frame>3 ,6, 12 months</time_frame>
    <description>with DASH scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of wrist pain and function</measure>
    <time_frame>3, 6,12 months</time_frame>
    <description>with PWRE scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of radiocarpal chondral lesions</measure>
    <time_frame>12 Months</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Intra-articular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>injection of microfat and plasma rich platelet PRP</intervention_name>
    <description>intra-articular injections</description>
    <arm_group_label>Intra-articular injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI 3T</description>
    <arm_group_label>Intra-articular injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females between 20 and 75 years of age&#xD;
&#xD;
          -  Symptomatic radio-carpal osteoarthritis diagnosed by arthroscanner resistant to&#xD;
             medical treatment and candidate to surgery&#xD;
&#xD;
          -  BMI ≥ 20 Kg/m²&#xD;
&#xD;
          -  Written informed consent, signed by patient or legal representative (if patient unable&#xD;
             to sign).&#xD;
&#xD;
          -  HB &gt; 10g/dl&#xD;
&#xD;
          -  Negative pregnancy test and efficiency contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Thrombocytopenia &lt; 150 G/L, Thrombocytosis &gt; 450 G/L, Thrombopathy&#xD;
&#xD;
          -  TP &lt; 70%, TCA patient / witness rapport &gt; 1,20&#xD;
&#xD;
          -  Anemia: HB &lt; 10g/dl&#xD;
&#xD;
          -  Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA&#xD;
&#xD;
          -  Treatment by platelet inhibiting agent, aspirin, antivitamin K completed more than 2&#xD;
             weeks before inclusion&#xD;
&#xD;
          -  Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks&#xD;
             before inclusion&#xD;
&#xD;
          -  Intra articular injection of corticosteroid or hyaluronic acid completed more than 8&#xD;
             weeks before inclusion&#xD;
&#xD;
          -  NSAI treatment completed more than 2 weeks before inclusion&#xD;
&#xD;
          -  Fever or recent disease completed more than 1 month before inclusion&#xD;
&#xD;
          -  Auto immune disease, Inflammatory or microcrystalline Arthritis, Immune deficit&#xD;
&#xD;
          -  Infectious disease&#xD;
&#xD;
          -  MRI contraindication: ocular loose bodies, pace maker, neurostimulator, cochlear&#xD;
             implant, vascular clips, metallic cardiac val&#xD;
&#xD;
          -  Anesthesia or surgery contra indication, iodine allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Regis LEGRE</last_name>
    <phone>0413429272</phone>
    <email>regis.legre@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DRCI</last_name>
    <phone>0491382747</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assisatnce Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

